Gilead’s Vemlidy expands label to treat paediatric chronic HBV
Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.
Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.
What's Your Reaction?
